NiCord is a cell therapy commercialized by Gamida Cell, with a leading Pre-Registration program in Hematopoietic Stem Cell Transplantation. According to Globaldata, it is involved in 7 clinical trials, of which 5 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of NiCord’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for NiCord is expected to reach an annual total of $159 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Omidubicel (Nicord) is under development for the treatment of hemoglobinopathies including sickle cell disease, beta-thalassemia, aplastic anemia and hematological malignancies like chronic myelocytic leukemia (CML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS) and for the use in hematopoietic stem cell transplantation. The therapeutic candidate is administered as an infusion. It is an allogeneic ex-vivo-expanded umbilical cord blood-derived hematopoietic CD34 positive progenitor cells and allogeneic non-expanded umbilical cord blood-derived hematopoietic mature myeloid and lymphoid cells. The therapeutic candidate is developed based on NAM platform technology. It was also under development for the treatment of Hodgkin lymphoma and non-Hodgkin lymphoma, acute myelocytic leukemia (AML).
Gamida Cell Overview
Gamida Cell (Gamida) is a health care company. It offers cell therapy developing cell and immune therapy technologies for treating blood cancers and serious blood disorders. Its pipeline products include Omidubicel an advanced cell therapy being developed as an allogeneic hematopoietic stem cell (bone marrow) transplant solution for treating hematologic malignancies and severe aplastic anemia; GDA-201 an innate natural killer cell immunotherapy used for the treatment of hematologic and solid tumors. Gamida utilizes NAM technology platform to develop its products. Gamida is headquartered in Jerusalem, Israel.
The operating loss of the company was US$87.2 million in FY2021, compared to an operating loss of US$60.9 million in FY2020. The net loss of the company was US$89.8 million in FY2021, compared to a net loss of US$61.6 million in FY2020.
For a complete picture of NiCord’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.